{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T11:52:09Z","timestamp":1789991529059,"version":"4.0.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AI099575"],"award-info":[{"award-number":["R21AI099575"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.vaccine.2015.03.063","type":"journal-article","created":{"date-parts":[[2015,4,9]],"date-time":"2015-04-09T23:00:11Z","timestamp":1428620411000},"page":"2307-2315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"title":["M2e-immobilized gold nanoparticles as influenza A vaccine: Role of soluble M2e and longevity of protection"],"prefix":"10.1016","volume":"33","author":[{"given":"Wenqian","family":"Tao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvinder S.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2015.03.063_bib0225","series-title":"Influenza (seasonal)","author":"WHO","year":"2014"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0230","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1750-2659.2011.00231.x","article-title":"The first influenza pandemic of the new millennium","volume":"5","author":"Neumann","year":"2011","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0235","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3201\/eid1201.051254","article-title":"Influenza pandemics of the 20th century","volume":"12","author":"Kilbourne","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0240","article-title":"Avian influenza A (H5N1) infection in humans","volume":"353","author":"Beigel","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0245","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/S0264-410X(03)00071-9","article-title":"The annual production cycle for influenza vaccine","volume":"21","author":"Gerdil","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.0300-9475.2004.01382.x","article-title":"Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines","volume":"59","author":"Cox","year":"2004","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0255","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.immuni.2005.12.005","article-title":"Development of effective vaccines against pandemic influenza","volume":"24","author":"Subbarao","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0260","first-page":"76","article-title":"Avian influenza pandemic: not if, but when","volume":"32","author":"Allen","year":"2005","journal-title":"Pediatr Nurs"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0265","doi-asserted-by":"crossref","first-page":"10717","DOI":"10.1128\/JVI.76.21.10717-10723.2002","article-title":"Characterization of the 1918 Spanish influenza virus matrix gene segment","volume":"76","author":"Reid","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0270","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/0092-8674(85)90211-9","article-title":"Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface","volume":"40","author":"Lamb","year":"1985","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0275","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/0042-6822(91)90115-R","article-title":"Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds","volume":"183","author":"Holsinger","year":"1991","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0280","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1016\/j.vaccine.2006.05.082","article-title":"Improved design and intranasal delivery of an M2e-based human influenza A vaccine","volume":"24","author":"De Filette","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0285","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.vaccine.2007.10.062","article-title":"Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin","volume":"26","author":"Huleatt","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0290","doi-asserted-by":"crossref","DOI":"10.3201\/eid1303.061125","article-title":"Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1","volume":"13","author":"Tompkins","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0295","doi-asserted-by":"crossref","DOI":"10.1142\/S1793984414500044","article-title":"Synthesis and immunogenicity assessment of elastin-like polypeptide-M2e construct as an influenza antigen","volume":"4","author":"Ingrole","year":"2014","journal-title":"Nano LIFE"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0300","doi-asserted-by":"crossref","first-page":"e59081","DOI":"10.1371\/journal.pone.0059081","article-title":"M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A","volume":"8","author":"Iba\u00f1ez","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0305","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/13484","article-title":"A universal influenza A vaccine based on the extracellular domain of the M2 protein","volume":"5","author":"Neirynck","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0310","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1016\/j.vaccine.2004.02.021","article-title":"Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys","volume":"22","author":"Fan","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0315","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.vaccine.2008.12.034","article-title":"Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys","volume":"27","author":"Fu","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0320","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ces.2012.04.001","article-title":"Modular engineering of a microbially-produced viral capsomere vaccine for influenza","volume":"103","author":"Wibowo","year":"2013","journal-title":"Chem Eng Sci"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0325","doi-asserted-by":"crossref","first-page":"e0117203","DOI":"10.1371\/journal.pone.0117203","article-title":"Non-carrier nanoparticles adjuvant modular protein vaccine in a particle-dependent manner","volume":"10","author":"Seth","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0330","doi-asserted-by":"crossref","first-page":"e94051","DOI":"10.1371\/journal.pone.0094051","article-title":"Mucosal vaccination with recombinant lactobacillus casei-displayed cta1-conjugated consensus matrix protein-2 (sM2) induces broad protection against divergent influenza subtypes in BALB\/c mice","volume":"9","author":"Chowdhury","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0335","doi-asserted-by":"crossref","first-page":"15700","DOI":"10.1021\/jp061667w","article-title":"Turkevich method for gold nanoparticle synthesis revisited","volume":"110","author":"Kimling","year":"2006","journal-title":"J Phys Chem B"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0340","series-title":"Assembly and characterization of biomolecule-gold nanoparticle conjugates and their use in intracellular imaging nanobiotechnology protocols","first-page":"85","author":"Tkachenko","year":"2005"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0345","doi-asserted-by":"crossref","first-page":"10076","DOI":"10.1021\/ja0487269","article-title":"Rational and combinatorial design of peptide capping ligands for gold nanoparticles","volume":"126","author":"L\u00e9vy","year":"2004","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0350","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/nar\/30.7.1558","article-title":"Multiple thiol-anchor capped DNA\u2013gold nanoparticle conjugates","volume":"30","author":"Li","year":"2002","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0355","doi-asserted-by":"crossref","first-page":"9789","DOI":"10.1021\/jp034331k","article-title":"Structure of dithiothreitol monolayers on Au (111)","volume":"107","author":"MacDairmid","year":"2003","journal-title":"J Phys Chem B"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0360","doi-asserted-by":"crossref","first-page":"12229","DOI":"10.1021\/jp074293v","article-title":"Gold nanoparticles decorated with oligo (ethylene glycol) thiols: protein resistance and colloidal stability","volume":"111","author":"Zhang","year":"2007","journal-title":"J Phys Chem A"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0365","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jcis.2014.03.052","article-title":"Gold nanoparticles decorated with oligo (ethylene glycol) thiols: surface charges and interactions with proteins in solution","volume":"426","author":"Schollbach","year":"2014","journal-title":"J Colloid Interface Sci"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0370","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1016\/j.vaccine.2014.04.043","article-title":"Co-administration of non-carrier nanoparticles boosts antigen immune response without requiring protein conjugation","volume":"32","author":"Wibowo","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0375","doi-asserted-by":"crossref","first-page":"e17642","DOI":"10.1371\/journal.pone.0017642","article-title":"Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases","volume":"6","author":"Ulery","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0380","doi-asserted-by":"crossref","DOI":"10.1038\/srep03775","article-title":"A systems approach to designing next generation vaccines: combining \u03b1-galactose modified antigens with nanoparticle platforms","volume":"4","author":"Phanse","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0385","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.vaccine.2013.11.069","article-title":"Nanoparticle vaccines","volume":"32","author":"Zhao","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0390","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/mt.2012.246","article-title":"Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus","volume":"21","author":"Kim","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0395","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood-2003-08-2972","article-title":"Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help","volume":"103","author":"Poeck","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0400","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.coviro.2013.05.004","article-title":"Virus-induced humoral immunity: on how B cell responses are initiated","volume":"3","author":"Zabel","year":"2013","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0405","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/13590849762411","article-title":"Management of rheumatoid arthritis: rationale for the use of colloidal metallic gold","volume":"7","author":"Abraham","year":"1997","journal-title":"J Nutr Environ Med"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0410","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1007\/s11671-009-9334-6","article-title":"Assessment of the in vivo toxicity of gold nanoparticles","volume":"4","author":"Chen","year":"2009","journal-title":"Nanoscale Res Lett"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0415","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.taap.2008.12.023","article-title":"Acute toxicity and pharmacokinetics of 13 nm-sized PEG-coated gold nanoparticles","volume":"236","author":"Cho","year":"2009","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0420","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1039\/C0CS00018C","article-title":"Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies","volume":"40","author":"Khlebtsov","year":"2011","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0425","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.bbrc.2010.02.046","article-title":"Bioaccumulation and toxicity of gold nanoparticles after repeated administration in mice","volume":"393","author":"Lasagna-Reeves","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0430","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1021\/ar800035u","article-title":"Gold nanoparticles in biology: beyond toxicity to cellular imaging","volume":"41","author":"Murphy","year":"2008","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0435","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.colsurfb.2008.07.004","article-title":"Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size","volume":"66","author":"Sonavane","year":"2008","journal-title":"Colloids Surf B: Biointerfaces"},{"key":"10.1016\/j.vaccine.2015.03.063_bib0440","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s11051-008-9561-2","article-title":"ICP-MS: a powerful technique for quantitative determination of gold nanoparticles without previous dissolving","volume":"11","author":"Allabashi","year":"2009","journal-title":"J Nanopart Res"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15003825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15003825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,23]],"date-time":"2018-09-23T18:59:11Z","timestamp":1537729151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15003825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":44,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0264410X15003825"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.03.063","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"M2e-immobilized gold nanoparticles as influenza A vaccine: Role of soluble M2e and longevity of protection","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.03.063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}